Meeting
2023 ASCO Genitourinary Cancers Symposium
Systematic literature review and testing of HER2 status in urothelial carcinoma (UC).
Authors
Vadim S Koshkin
University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Vadim S Koshkin , Christine Boyiddle , Naomi Schwartz , Judy Yu , Kristina S. Yu , Ashley Kang , Lisa Bloudek , Qijun Fang , Johanna M. Schafer , Amanda F. Baker , Farzaneh H. Sayedian , Emilie Scherrer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 556)
DOI
10.1200/JCO.2023.41.6_suppl.556
Abstract #
556
Poster Bd #
M19
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A comparison of immunohistochemistry (IHC) and dual-color silver in situ hybridization (SISH) with a novel method combining both gene and protein platforms on a unique slide for testing the HER2 in gastric carcinoma.
First Author: Dominique Werner
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613.
First Author: Kanwal Pratap Singh Raghav
Poster
2023 ASCO Annual Meeting
Whole-genome sequencing based assessment of HER2 focal amplification for precision oncology of breast cancers.
First Author: Ryul Kim
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The HORIZON III retrospective exploratory analysis: HER2 expression amplification in colorectal cancer.
First Author: Fabiola Cecchi